X4 Pharmaceuticals Says FDA Agreed To Reduce Phase 3 4WARD Chronic Neutropenia Trial Size From 176 To 126 Participants; Expects Enrollment Completion By Year-End 2026, Topline Data In H1 2028
Share
Why It Matters
X4 Pharma is testing a new medicine for a blood condition, and the FDA said they can use fewer patients in their big trial—176 down to 126. This means the company might finish testing faster and show results sooner, which is good news for their schedule.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.